Long term responders to palliative chemotherapy for advanced biliary tract cancer.

2.50
Hdl Handle:
http://hdl.handle.net/10541/620399
Title:
Long term responders to palliative chemotherapy for advanced biliary tract cancer.
Authors:
Doherty, M; McNamara, Mairéad G ( 0000-0002-2272-3678 ) ; Aneja, P; McInerney, E; Moignard, S; Horgan, A; Jiang, H; Panzarella, T; Jang, R; Dhani, N; Hedley, D; Knox, J
Abstract:
Patients with advanced biliary tract cancer (BTC) are often treated with palliative chemotherapy (PC). Standard PC since 2010 is a cisplatin/gemcitabine doublet, with median overall survival (OS) of 11.7 months from the ABC-02 trial. Prior to this, our institutional standard was gemcitabine and fluoropyrimidine. The ABC-02 study used 8 cycles of PC as standard with treatment stopped even in the absence of disease progression, but some patients may benefit from continuing PC longer than 8 cycles.
Affiliation:
Department of Medical Oncology, Princess Margaret Cancer Centre, Toronto, Ontario, Canada
Citation:
Long term responders to palliative chemotherapy for advanced biliary tract cancer. 2017, 8 (2):352-360 J Gastrointest Oncol
Journal:
Journal of Gastrointestinal Oncology
Issue Date:
Apr-2017
URI:
http://hdl.handle.net/10541/620399
DOI:
10.21037/jgo.2017.03.06
PubMed ID:
28480074
Type:
Article
Language:
en
ISSN:
2078-6891
Appears in Collections:
All Christie Publications

Full metadata record

DC FieldValue Language
dc.contributor.authorDoherty, Men
dc.contributor.authorMcNamara, Mairéad Gen
dc.contributor.authorAneja, Pen
dc.contributor.authorMcInerney, Een
dc.contributor.authorMoignard, Sen
dc.contributor.authorHorgan, Aen
dc.contributor.authorJiang, Hen
dc.contributor.authorPanzarella, Ten
dc.contributor.authorJang, Ren
dc.contributor.authorDhani, Nen
dc.contributor.authorHedley, Den
dc.contributor.authorKnox, Jen
dc.date.accessioned2017-06-29T10:08:49Z-
dc.date.available2017-06-29T10:08:49Z-
dc.date.issued2017-04-
dc.identifier.citationLong term responders to palliative chemotherapy for advanced biliary tract cancer. 2017, 8 (2):352-360 J Gastrointest Oncolen
dc.identifier.issn2078-6891-
dc.identifier.pmid28480074-
dc.identifier.doi10.21037/jgo.2017.03.06-
dc.identifier.urihttp://hdl.handle.net/10541/620399-
dc.description.abstractPatients with advanced biliary tract cancer (BTC) are often treated with palliative chemotherapy (PC). Standard PC since 2010 is a cisplatin/gemcitabine doublet, with median overall survival (OS) of 11.7 months from the ABC-02 trial. Prior to this, our institutional standard was gemcitabine and fluoropyrimidine. The ABC-02 study used 8 cycles of PC as standard with treatment stopped even in the absence of disease progression, but some patients may benefit from continuing PC longer than 8 cycles.en
dc.language.isoenen
dc.rightsArchived with thanks to Journal of gastrointestinal oncologyen
dc.titleLong term responders to palliative chemotherapy for advanced biliary tract cancer.en
dc.typeArticleen
dc.contributor.departmentDepartment of Medical Oncology, Princess Margaret Cancer Centre, Toronto, Ontario, Canadaen
dc.identifier.journalJournal of Gastrointestinal Oncologyen

Related articles on PubMed

All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.